Debra G Silberg
Overview
Explore the profile of Debra G Silberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Silberg D, Dubow J, Bast A
Gastroenterology
. 2024 Jan;
166(5):941-942.
PMID: 38242236
No abstract available.
2.
Vos M, Dimick-Santos L, Mehta R, Omokaro S, Taminiau J, Schabel E, et al.
Gastroenterology
. 2019 Sep;
157(6):1448-1456.e1.
PMID: 31520612
No abstract available.
3.
Palmer M, Jennings L, Silberg D, Bliss C, Martin P
BMC Pharmacol Toxicol
. 2018 Mar;
19(1):10.
PMID: 29548345
Background: Accumulation of toxic free cholesterol in hepatocytes may cause hepatic inflammation and fibrosis. Volixibat inhibits bile acid reuptake via the apical sodium bile acid transporter located on the luminal...
4.
Flood E, Silberg D, Romero B, Beusterien K, Erder M, Cuffari C
BMC Res Notes
. 2017 Sep;
10(1):491.
PMID: 28946891
Background: The purpose of this study is to develop patient-reported (PRO) and observer-reported (ObsRO) outcome measures of ulcerative colitis (UC) signs/symptoms in children aged 5-17 with mild/moderate UC. The daily...
5.
Siebers N, Palmer M, Silberg D, Jennings L, Bliss C, Martin P
Eur J Drug Metab Pharmacokinet
. 2017 Jul;
43(1):91-101.
PMID: 28702877
Background And Objectives: Volixibat is a potent inhibitor of the apical sodium-dependent bile acid transporter in development for the treatment of nonalcoholic steatohepatitis. This phase 1, open-label study investigated the...
6.
Fuller G, Bolus R, Whitman C, Talley J, Erder M, Joseph A, et al.
Dig Dis Sci
. 2017 Jan;
62(3):593-606.
PMID: 28116591
Background: Most patients with gastroesophageal reflux disease (GERD) experience relief following treatment with proton pump inhibitors (PPIs) (Vakil et al. in Am J Gastroenterol 101:1900-1920, 2006; Everhart and Ruhl in...
7.
Taylor F, Reasner D, Carson R, Deal L, Foley C, Iovin R, et al.
Patient
. 2016 Mar;
9(5):409-18.
PMID: 27020447
Objectives: The aim was to document, from the perspective of the empirical literature, the primary symptoms of functional dyspepsia (FD), evaluate the extent to which existing questionnaires target those symptoms,...
8.
Miner Jr P, Silberg D, Ruth M, Miller F, Pandolfino J
BMC Gastroenterol
. 2014 Nov;
14:188.
PMID: 25407279
Background: The γ-aminobutyric acid type B-receptor agonist lesogaberan (AZD3355) has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy (partial responders)....
9.
Sharma P, Vakil N, Monyak J, Silberg D
J Clin Gastroenterol
. 2013 Feb;
47(8):672-7.
PMID: 23442835
Background: Obesity is associated with increased risk of gastroesophageal reflux disease (GERD). Goal: To evaluate the effect of obesity on symptom resolution in patients with nonerosive reflux disease (NERD) and...
10.
Shaheen N, Denison H, Bjorck K, Silberg D
Am J Gastroenterol
. 2013 Jan;
108(4):529-34.
PMID: 23318482
Objectives: Approximately 20-30% of patients with gastroesophageal reflux disease (GERD) do not experience complete symptom resolution during proton pump inhibitor (PPI) therapy. The aim of this study was to determine...